SCIENTIFIC LITERATURE · MED

Clinical Review Report: Safinamide (Onstryv): (Valeo Pharma Inc.): Indication: For add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing “off” episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD

· 2020-05-01

PMID: 33231957

Research overview

This section identifies the original publication. Follow the source for its authors and journal.

Assess the question within the original study’s scope.

Check the source article for study design and sample details.

An editorially approved findings summary is not yet published for this record.

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.